Why the study?
Guidelines recommend beta-blockers and flecainide for idiopathic PVCs, but acknowledge limited evidence supporting this recommendation.
Does flecainide reduce PVC burden more effectively than carvedilol in patients with idiopathic premature ventricular complexes from the ventricular outflow tract without structural heart disease?
Does flecainide reduce PVC burden more effectively than carvedilol in patients with idiopathic premature ventricular complexes from the ventricular outflow tract without structural heart disease?
Both flecainide and carvedilol effectively suppress outflow tract PVCs in patients without structural heart disease, but flecainide demonstrates superior efficacy.
No takes yet. Share an insight, caveat, or question.
Flecainide reduced PVC burden more than carvedilol; extends limited RCT evidence supporting class Ic preference for idiopathic OT PVCs.
Hwang et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: